Treatment response in psychotic patients classified according to social and clinical needs, drug side effects, and previous treatment; a method to identify functional remission

被引:5
作者
Alenius, Malin [1 ,2 ]
Hammarlund-Udenaes, Margareta [2 ]
Hartvig, Per [3 ]
Sundquist, Staffan [4 ]
Lindstrom, Leif [5 ]
机构
[1] Apoteket AB, S-11881 Stockholm, Sweden
[2] Uppsala Univ, Dept Pharmaceut Biosci, S-75124 Uppsala, Sweden
[3] Univ Copenhagen, Sect Pharmacokinet, Dept Pharmacol & Pharmacotherapy, DK-2100 Copenhagen, Denmark
[4] Apoteket Qulturum, S-55120 Jonkoping, Sweden
[5] Uppsala Univ, Dept Neurosci, S-75185 Uppsala, Sweden
关键词
DEFINING TREATMENT REFRACTORINESS; SEVERE MENTAL-ILLNESS; LONG-TERM; CAMBERWELL ASSESSMENT; ANTIPSYCHOTIC-DRUGS; EXTRAPYRAMIDAL SYMPTOMS; PROLACTIN-RELEASE; SCHIZOPHRENIA; RELIABILITY; PREVENTION;
D O I
10.1016/j.comppsych.2008.11.001
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Various approaches have been made over the years to classify psychotic patients according to inadequate treatment response, using terms such as treatment resistant or treatment refractory Existing classifications have been criticized for overestimating positive symptoms; underestimating residual symptoms, negative symptoms, and side effects; or being to open for individual interpretation. The aim of this study was to present and evaluate a new method of classification according to treatment response and, thus, to identify patients in functional remission. Method: A naturalistic, cross-sectional study was performed using patient interviews and information from patient files. The new classification method CANSEPT, which combines the Camberwell Assessment of Need rating scale, the Udvalg for Kliniske Undersogelser side effect rating scale (SE), and the patient's previous treatment history (PT), was used to group the patients according to treatment response. CANSEPT was evaluated by comparison of expected and observed results. Results: In the patient population (n = 123), the patients in functional remission, as defined by CANSEPT, had higher quality of life, fewer hospitalizations, fewer psychotic symptoms, and higher rate of workers than those with the worst treatment outcome. Conclusion: In the evaluation, CANSEPT showed validity in discriminating the patients of interest and was well tolerated by the patients. CANSEPT could secure inclusion of correct patients in the clinic or in research. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:453 / 462
页数:10
相关论文
共 61 条
[1]   Remission in schizophrenia: Proposed criteria and rationale for consensus [J].
Andreasen, NC ;
Carpenter, WT ;
Kane, JM ;
Lasser, RA ;
Marder, SR ;
Weinberger, DR .
AMERICAN JOURNAL OF PSYCHIATRY, 2005, 162 (03) :441-449
[2]   Test-retest reliability of the Camberwell Assessment of Need (CAN) [J].
Arvidsson, H .
NORDIC JOURNAL OF PSYCHIATRY, 2003, 57 (04) :279-283
[3]  
Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
[4]   Body weight gain induced by antipsychotic drugs: mechanisms and management [J].
Baptista, T .
ACTA PSYCHIATRICA SCANDINAVICA, 1999, 100 (01) :3-16
[5]   Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin [J].
Bartolucci, Alfred A. ;
Howard, George .
AMERICAN JOURNAL OF CARDIOLOGY, 2006, 98 (06) :746-750
[6]   Dopamine as a prolactin (PRL) inhibitor [J].
Ben-Jonathan, N ;
Hnasko, R .
ENDOCRINE REVIEWS, 2001, 22 (06) :724-763
[7]  
Blair D T, 1992, Nurse Pract, V17, P62, DOI 10.1097/00006205-199211000-00018
[8]  
Blair D.T., 1992, Nurse Practice, V17, P67
[9]  
Borell Per, 1995, Scandinavian Journal of Behaviour Therapy, V24, P63
[10]   DEFINING TREATMENT REFRACTORINESS IN SCHIZOPHRENIA [J].
BRENNER, HD ;
DENCKER, SJ ;
GOLDSTEIN, MJ ;
HUBBARD, JW ;
KEEGAN, DL ;
KRUGER, G ;
KULHANEK, F ;
LIBERMAN, RP ;
MALM, U ;
MIDHA, KK .
SCHIZOPHRENIA BULLETIN, 1990, 16 (04) :551-561